Knight Therapeutics Inc (GUD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Knight Therapeutics Inc (GUD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH511336D
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Knight Therapeutics Inc (Knight Therapeutics) is a specialty pharmaceutical company focused on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. Its consumer health products are used in the treatment of metabolic diseases, dermatological ailments, osteoarthritis, and pain associated with diabetic and peripheral neuropathy, among others. Knight Therapeutics offers medical devices for prostate ablation surgery and detection of peripheral arterial disease. The company develops drugs for treatment of various therapeutic areas such as bacterial conjunctivitis, oesophageal cancer, endobronchial cancer, diabetic macular edema, opioid addiction, and chronic pain and inflammation, among others. It partners with other companies to sell their products. Knight Therapeutics is headquartered in Montreal, Quebec, Canada.

Knight Therapeutics Inc (GUD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Knight Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Knight Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Knight Therapeutics Acquires ATryn and Photofrin from Orphan Canada 14

Partnerships 16

3D Signatures and Plicit Capital Enters into Licensing Agreement with Knight Therapeutics 16

Knight Therapeutics Enters into Licensing Agreement with Pro Bono Bio 17

Knight Therapeutics Expands Distribution Agreement with Ember Therapeutics 18

Knight Therapeutics Enters into Distribution Agreement with Akorn 19

Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 20

Licensing Agreements 21

Knight Therapeutics Enters into Licensing Agreement with Jaguar Health 21

Knight Therapeutics Enters into Licensing Agreement with TherapeuticsMD 22

Knight Therapeutics Enters into Licensing Agreement with Ardelyx 23

Knight Therapeutics Enters into Licensing Agreement with AstraZeneca for Movantik 24

SIFI Enters into Licensing Agreement with Knight Therapeutics 25

Knight Therapeutics Enters into Licensing Agreement with Medimetriks Pharma 26

Knight Therapeutics Enters into Licensing Agreement with Braeburn Pharma for Probuphine 27

Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 28

Knight Therapeutics Enters into Licensing Agreement with 60 Degrees Pharma 29

Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 30

Knight Therapeutics Enters into Licensing Agreement with Advaxis 31

Equity Offering 32

Knight Therapeutics to Raise USD65 Million in Private Placement of Shares 32

Knight Therapeutics Raises USD176 Million in Public Offering of Shares 34

Advaxis Raises USD25 Million in Private Placement of Shares 36

Knight Therapeutics Raises USD76.5 Million in Public Offering of Shares 38

Knight Therapeutics Completes Private Placement Of Warrants For USD 160 Million 39

Asset Transactions 40

Synergy Strips to Acquire US Rights of Neuragen from Knight Therapeutics for USD1.2 Million 40

Acquisition 41

Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 41

Knight Therapeutics Acquires 16% of Stake in Pediapharm 42

Knight Therapeutics Acquires 28.3% Stake in Medison Biotech for USD60.3 Million 43

Knight Therapeutics Acquires NeurAxon for USD1.5 Million 44

Knight Therapeutics Inc-Key Competitors 45

Knight Therapeutics Inc-Key Employees 46

Knight Therapeutics Inc-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Recent Developments 48

Financial Announcements 48

May 10, 2018: Knight Reports First Quarter 2018 Results 48

Mar 15, 2018: Knight Reports 2017 Fourth Quarter and Year End Results 49

Nov 09, 2017: Knight Reports Third Quarter 2017 Results 51

Aug 10, 2017: Knight Reports Second Quarter 2017 Results 53

May 11, 2017: Knight Reports First Quarter 2017 Results 55

Mar 16, 2017: Knight Reports Fourth Quarter and Year-Ended December 31, 2016 Results 56

Corporate Communications 57

Oct 10, 2017: Knight Announces Changing of the Finance Guard 57

Feb 23, 2017: Knight Therapeutics Announces Board Change 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59

List of Figures

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Knight Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Knight Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Knight Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Knight Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Knight Therapeutics Acquires ATryn and Photofrin from Orphan Canada 14

3D Signatures and Plicit Capital Enters into Licensing Agreement with Knight Therapeutics 16

Knight Therapeutics Enters into Licensing Agreement with Pro Bono Bio 17

Knight Therapeutics Expands Distribution Agreement with Ember Therapeutics 18

Knight Therapeutics Enters into Distribution Agreement with Akorn 19

Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 20

Knight Therapeutics Enters into Licensing Agreement with Jaguar Health 21

Knight Therapeutics Enters into Licensing Agreement with TherapeuticsMD 22

Knight Therapeutics Enters into Licensing Agreement with Ardelyx 23

Knight Therapeutics Enters into Licensing Agreement with AstraZeneca for Movantik 24

SIFI Enters into Licensing Agreement with Knight Therapeutics 25

Knight Therapeutics Enters into Licensing Agreement with Medimetriks Pharma 26

Knight Therapeutics Enters into Licensing Agreement with Braeburn Pharma for Probuphine 27

Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 28

Knight Therapeutics Enters into Licensing Agreement with 60 Degrees Pharma 29

Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 30

Knight Therapeutics Enters into Licensing Agreement with Advaxis 31

Knight Therapeutics to Raise USD65 Million in Private Placement of Shares 32

Knight Therapeutics Raises USD176 Million in Public Offering of Shares 34

Advaxis Raises USD25 Million in Private Placement of Shares 36

Knight Therapeutics Raises USD76.5 Million in Public Offering of Shares 38

Knight Therapeutics Completes Private Placement Of Warrants For USD 160 Million 39

Synergy Strips to Acquire US Rights of Neuragen from Knight Therapeutics for USD1.2 Million 40

Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 41

Knight Therapeutics Acquires 16% of Stake in Pediapharm 42

Knight Therapeutics Acquires 28.3% Stake in Medison Biotech for USD60.3 Million 43

Knight Therapeutics Acquires NeurAxon for USD1.5 Million 44

Knight Therapeutics Inc, Key Competitors 45

Knight Therapeutics Inc, Key Employees 46

Knight Therapeutics Inc, Subsidiaries 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Knight Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com